Beyond Air, Inc.

XAIR

NASDAQ

Healthcare

Medical - Devices

Garden City, NY, US107 employeesbeyondair.net

$0.70

-0.01(-1.99%)

Mkt Cap $4M

$0.67

$5.70

52-Week Range

At a Glance

AI-generated

8-K

Beyond Air, Inc. announced the resignation of CEO and Director Steven A. Lisi, effective March 27, 2026, and the appointment of Robert Goodman as his successor, alongside a separation agreement providing $650,000 in compensation continuation and equity acceleration.

$4M

Market Cap

$4M

Revenue

-$18M

Net Income

Employees107

Fundamentals

How The Business Makes Money

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

Industry Medical - Devices

Activity

What Changed Recently

Material Agreement

Mar 31, 2026

| Entry into a Material Definitive Agreement. | |---|---| The description in Item 5.02 below, as it relates to the terms and conditions of the Separation and Re

Financial Results

Feb 12, 2026

. Results of Operations and Financial Condition. On February 13, 2026, Beyond Air, Inc. (the “Company”) issued a press release announcing certain financial resu

Material Agreement

Jan 19, 2026

. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhib

Shareholder Vote

Feb 1, 2026

Submission of Matters to a Vote of Security Holders On January 30, 2026, Beyond Air, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Ann

Other Event

Jan 14, 2026

Other Events On January 13, 2026, Beyond Air, Inc. (“Beyond Air” or the “Company”) issued a press release announcing that XTL Biopharmaceuticals Ltd. (“XTL”) (N

Peer Companies

Company	Price	Change	Market Cap	P/E
IINNInspira Technologies Oxy ...	$0.48	+6.25%	$12M	-2.4
AEONAEON Biopharma, Inc.	$0.94	-3.70%	$11M	—
LFWDLifeward Ltd.	$6.85	+0.74%	$10M	-0.5
BOLTBolt Biotherapeutics, Inc...	$4.45	-1.33%	$9M	-0.2
CLRBCellectar Biosciences, In...	$2.60	+4.00%	$8M	-0.6
SINTSintx Technologies, Inc.	$2.53	-0.78%	$7M	-0.4
TRIBTrinity Biotech plc	$0.60	+0.99%	$6M	-0.3
TNONTenon Medical, Inc.	$0.72	+2.58%	$5M	-0.7

Analyst View

Company Profile

CIK0001641631

ISINUS08862L2025

CUSIP08862L202

Phone516 665 8200

Address900 Stewart Avenue, Garden City, NY, 11530, US

SEC EDGAR